Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107605
Title: | Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment | Authors: | Coimbra, Judite R. M. Marques, Daniela F. F. Baptista, Salete J. Pereira, Cláudia Fragão Moreira, Paula I. Dinis, Teresa C. P. Santos, Armanda E. Salvador, Jorge A. R. |
Keywords: | Alzheimer’s Disease (AD); Amyloid-β (Aβ); BACE1; inhibitors; small molecules; drug discovery and development | Issue Date: | 2018 | Publisher: | Frontiers Media S.A. | Project: | project CENTRO-01-0247-FEDER-003269, drugs2CAD project CENTRO-01-0145-FEDER-000012-HealthyAging2020 project POCI-01-0145-FEDER-007440 |
Serial title, monograph or event: | Frontiers in Chemistry | Volume: | 6 | Issue: | MAY | Abstract: | Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade. | URI: | https://hdl.handle.net/10316/107605 | ISSN: | 2296-2646 | DOI: | 10.3389/fchem.2018.00178 | Rights: | openAccess |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Highlights in BACE1 inhibitors for Alzheimer's disease treatment.pdf | 1.28 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
124
checked on Apr 22, 2024
WEB OF SCIENCETM
Citations
114
checked on Apr 2, 2024
Page view(s)
67
checked on Apr 23, 2024
Download(s)
26
checked on Apr 23, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License